Tags

Type your tag names separated by a space and hit enter

A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Int J STD AIDS. 2009 Oct; 20(10):690-5.IJ

Abstract

This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged >or=18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2-14 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: -4.5, 1.6) and intent-to-treat (95% CI: -5.8, 6.9) populations. Clinical success rates at 21-35 days post-therapy were 93.8% (166/177; data missing for 47 patients) for moxifloxacin and 91.3% (147/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2-14 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID.

Authors+Show Affiliations

Department of Family Medicine, University of Pretoria, Pretoria, South Africa.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19815913

Citation

Heystek, M, et al. "A Randomized Double-blind Comparison of Moxifloxacin and Doxycycline/metronidazole/ciprofloxacin in the Treatment of Acute, Uncomplicated Pelvic Inflammatory Disease." International Journal of STD & AIDS, vol. 20, no. 10, 2009, pp. 690-5.
Heystek M, Ross JD, PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS. 2009;20(10):690-5.
Heystek, M., & Ross, J. D. (2009). A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. International Journal of STD & AIDS, 20(10), 690-5. https://doi.org/10.1258/ijsa.2008.008495
Heystek M, Ross JD, PID Study Group. A Randomized Double-blind Comparison of Moxifloxacin and Doxycycline/metronidazole/ciprofloxacin in the Treatment of Acute, Uncomplicated Pelvic Inflammatory Disease. Int J STD AIDS. 2009;20(10):690-5. PubMed PMID: 19815913.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. AU - Heystek,M, AU - Ross,J D C, AU - ,, PY - 2009/10/10/entrez PY - 2009/10/10/pubmed PY - 2009/12/19/medline SP - 690 EP - 5 JF - International journal of STD & AIDS JO - Int J STD AIDS VL - 20 IS - 10 N2 - This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged >or=18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2-14 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: -4.5, 1.6) and intent-to-treat (95% CI: -5.8, 6.9) populations. Clinical success rates at 21-35 days post-therapy were 93.8% (166/177; data missing for 47 patients) for moxifloxacin and 91.3% (147/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2-14 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID. SN - 0956-4624 UR - https://www.unboundmedicine.com/medline/citation/19815913/A_randomized_double_blind_comparison_of_moxifloxacin_and_doxycycline/metronidazole/ciprofloxacin_in_the_treatment_of_acute_uncomplicated_pelvic_inflammatory_disease_ L2 - https://journals.sagepub.com/doi/10.1258/ijsa.2008.008495?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -